Show simple item record

dc.contributor.authorSeamon, Leigh G*
dc.contributor.authorJava, James J*
dc.contributor.authorMonk, Bradley J*
dc.contributor.authorPenson, Richard T*
dc.contributor.authorBrown, Jubilee*
dc.contributor.authorMannel, Robert S*
dc.contributor.authorOaknin, Anna*
dc.contributor.authorLeitao, Mario M*
dc.contributor.authorEisenhauer, Eric L*
dc.contributor.authorLong, Harry J*
dc.contributor.authorLiao, Shu Y*
dc.contributor.authorTewari, Krishnansu S*
dc.date.accessioned2018-02-12T16:15:37Z
dc.date.available2018-02-12T16:15:37Z
dc.date.issued2017-11-28
dc.identifier.citationImpact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study 2017, 118 (2):162 British Journal of Canceren
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.pmid29182608
dc.identifier.doi10.1038/bjc.2017.400
dc.identifier.urihttp://hdl.handle.net/10150/626543
dc.description.abstractBackground: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcinoma (SCCA) of the cervix. It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab. Methods: Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets. Pearson's test was used to evaluate response rate (RR) of AC/AS vs SCCA, Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS), and Cox proportional hazards model to estimate the impact of histology on PFS and OS. Results: Of 781 evaluable patients, 77% (N = 599) had SCCA and 23% (N = 182) AC/AS. There were no significant differences in RRs between histologic subgroups. The adjusted hazard ratio (HR) for death for SCCA vs AC/AS was 1.13 (95% CI 0.93, 1.38 P = 0.23). When comparing SC/AS (N = 661, 85%) to AC alone (N = 120, 15%), the adjusted HR for death was 1.23 (95% CI 0.97, 1.57, P = 0.09). Conclusions: AC/AS and SCCA have similar survival in recurrent or metastatic cervical carcinoma when treated with chemotherapy doublets.
dc.language.isoenen
dc.publisherNATURE PUBLISHING GROUPen
dc.relation.urlhttp://www.nature.com/doifinder/10.1038/bjc.2017.400en
dc.rights© 2018 Cancer Research UK. All rights reserved.en
dc.subjectcervical canceren
dc.subjectadenocarcinomaen
dc.subjectsquamousen
dc.subjectantiangiogenesisen
dc.subjectbevacizumaben
dc.titleImpact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Studyen
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Ctr Cancen
dc.identifier.journalBritish Journal of Canceren
dc.description.note12 month embargo; Published online: 28 November 2017 / Creative Commons Attribution-NonCommercial-Share-Alike 3.0en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
html.description.abstractBackground: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcinoma (SCCA) of the cervix. It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab. Methods: Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets. Pearson's test was used to evaluate response rate (RR) of AC/AS vs SCCA, Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS), and Cox proportional hazards model to estimate the impact of histology on PFS and OS. Results: Of 781 evaluable patients, 77% (N = 599) had SCCA and 23% (N = 182) AC/AS. There were no significant differences in RRs between histologic subgroups. The adjusted hazard ratio (HR) for death for SCCA vs AC/AS was 1.13 (95% CI 0.93, 1.38 P = 0.23). When comparing SC/AS (N = 661, 85%) to AC alone (N = 120, 15%), the adjusted HR for death was 1.23 (95% CI 0.97, 1.57, P = 0.09). Conclusions: AC/AS and SCCA have similar survival in recurrent or metastatic cervical carcinoma when treated with chemotherapy doublets.


Files in this item

Thumbnail
Name:
bjc2017400.pdf
Size:
1.087Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record